Impact of regulatory measures on the approval timelines of advanced therapy medicinal products by the European Medicines Agency
IntroductionThe study examines the impact of regulatory tools, including PRIority MEdicines (PRIME) scheme, on the marketing authorization (MA) timeline of advanced therapy medicinal products (ATMPs) approved by the European Medicines Agency (EMA).MethodsA retrospective analysis of EMA-approved ATMP...
Saved in:
Main Authors: | Simonita Alaburde, Justinas Ivaska, Greta Kaspute, Tatjana Ivaskiene |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-06-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1623689/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advanced-Therapy Medicinal Products: Challenges for Implementation in Pediatric Clinical Practice
by: Yulia M. Gomon, et al.
Published: (2024-02-01) -
Quality control programmes for induced pluripotent stem cell-derived medicinal products
by: E. V. Melnikova, et al.
Published: (2025-06-01) -
Methodological Approaches to Risk Management of Advanced Therapy Medicinal Products
by: A. A. Taube, et al.
Published: (2023-09-01) -
Association Between Hearing Loss and Systemic Small-Vessel Vasculitis: Audiological Aspects Across Disease Types
by: Vija Vainutienė, et al.
Published: (2025-06-01) -
TIMELINE FOR THE DOUBLE ANTIPLATELET THERAPY. FACTS AND SUGGESTIONS
by: O. L. Barbarash, et al.
Published: (2016-02-01)